HIV infection often results in MRI-detectable brain atrophy and white matter signal hyperintensities ( WMSHs). Magnetic resonance images were obtained from 31 HIV+ male patients and 10 high-risk controls. Variation within the HIV+ group on neuropsychological (NP) impairment and stage of systemic disease were relatively independent, allowing examination of the relative association of MRI measures with NP impairment versus with systemic stage of disease. HIV+ patients compared to high-risk controls evidenced global atrophy, reduced caudate nuclei volume, and a trend to gray matter volume loss but no difference in white matter volume or in WMSHs. These effects were progressive with CDC clinical stage such that patients at CDC stage A had values very close to those of controls, while patients at CDC stage C had the most abnormal values. In contrast, the relationship between these MRI variables and seventy of NP impairment was much less dramatic, with the mildly to moderately impaired HIV+ subjects showing MRI volume effects greater than or equal to those of the severely impaired HIV+ subjects. These results suggest that MRI-detectable brain atrophy secondary to HIV infection is not the primary substrate underlying the progressive NP impairment in HIV disease. (JINS, 1997.3, 276-287.) 
disease process. It is also unclear whether patients with minor cognitive-motor disorder will inevitably progress to HADC (American Academy of Neurology ADDS Task Force, 1991) .
While the presence of HADC in AIDS patients is an established phenomenon, the presence of less severe NP impairments in seropositive patients witbout symptomatic systemic disease remains controversial. The large Multicenter AIDS Cohort Study found the onset of HADC to be a fairly abrupt phenomenon, occurring only in late-stage patients. Their sample of HIV+ asymptomatic subjects (N = 727) did not differ significantly from seronegative subjects (N = 769) on any neuropsychological measure (Miller et al., 1990) . In contrast, Grant et al. (1992) and Janssen et al. (1989) documented mild NP impairment in clinically symptomatic (but not late-stage) patients. Stem et al. (1991) and Bornstein et al. (1993) found mild NP impairment in clinically asymptomatic patients, and Grant et al. (1992) , Levin et al. (1990) , and Wilkie et al. (1990) reported pro-gressive NP impairment in clinically asymptomatic patients. Recently, using an 8-hr NP battery, Heaton et al. (1995) documented NP impairment in 30.5% of asymptomatic HIV+ subjects (N = 249). Although the varying reports on the frequency of NP impairment in the earlier stages of HIV infection are difficult to assess (due to differences in exclusionary criteria for subjects and controls, in the extent and sensitivity of the cognitive batteries employed, and in definitions of impairment), a critical review of 57 NP studies of asymptomatic HIV+ individuals found asymptomatic HIV+ subjects to be almost 3 times more likely to be neuropsychologically impaired than their HIVcounterparts (median prevalence 35 vs. 12%, respectively; White et al., 1995) . Some of the structural effects on the brain of systemic HIV infection can be assessed in vivo using MRI. In most cases, MRI shows global brain atrophy in HIV+ subjects at some point in the course of the disease (Levin et al., 1990;  Moeller & Backmund, 1990; Post et al., 1991; Pan et al., 1992 ; Aylward et al., 1993 ; Hestad et al., 1993; Paley et al., 1994) . Global atrophy in patients with advanced disease is not universal. Seilhean et al. (1993) , in a postmortem study of the brains of 6 patients with HIV-associated cognitivemotor complex (4 of whom met the criteria of dementia) found no difference in cerebral weight between patients and controls. Loss of brain volume has been associated with dementia (Pan et al., 1992; Hestad et al., 1993) , advanced CDC stage (Paley et al., 1994) . and symptomatic but not demented patients (Jernigan et al., 1993) . Aylward et al. (1993) reported cerebral atrophy in 16 nondemented HIV+ patients compared to 10 HIV-controls. Half of the nondemented HIV+ group was asymptomatic. However, the HIV + group in their study included a proportionally greater number of individuals with histories of alcohol abuse, drug abuse, head injury, psychiatric illness, and positive medical histories than the HIV-group. These preexisting conditions may have contributed to Aylward's findings of cerebral atrophy in his nondemented HIV+ group, which included asymptomatic subjects.
While there have been abundant in vivo MRI investigations of global brain atrophy inJHIV+ subjects compared to HIV-controls, there have been few reports that address the differential loss or pathology of cortical gray matter, subcortical gray matter, and white matter. Jernigan et al. (1993) found that symptomatic HIV + subjects showed significant volume loss in white matter, temporal limbic gray matter, and the caudate nuclei when compared to both low-risk (i.e., heterosexual non-drug-abusing) HIV -controls and-asymptomatic HIV+ patients.
However, significant temporal-limbic and caudate nuclei volume loss were also present.in high-risk HIV-controls, complicating the interpretation of the gray matter losses in the symptomatic HIV+ subjects. Several other authors have also documented atrophy of the caudate nuclei in HIV+ subjects (Pan et al., 1992;  Aylward et al., 1993; Hestad et al., 1993; Jernigan et al., 1993) . Most of these investigators found caudate atrophy to be significantly associated with dementia. Some studies have attempted to measure WMSHs as a measure of white matter pathology ; Smith et al., 1990; Sonnerborg et al., 1990 ; Post et al., 1991; Manji et al., 1994) . Although postmortem studies show HIV infiltration and damage of the white matter, (Smith et al., 1990 ; Masliah et al., 1992a; Liuzzi et al., 1994) MRI studies generally do not find WMSHs to be significantly associated with HIV infection, at least until very latestage illness.
In summary, HIV disease progression is often associated with the development of atrophic brain changes and with the development of NP impairment. Unfortunately, severity of NP impairment has almost always been confounded with the progression of systemic disease in studies that have examined MRI-detectable brain atrophy in HIV infection. In the following report, we are able to separate the association of MRI changes with severity of N p impairment from the association o f MRI changes with severity of systemic disease due to a sampling design that resulted in the relative independence of NP impairment and clinical stage of systemic disease.
METHODS

Research Participants
Thirty-one gay or bisexual HIV+ male subjects (ages 38.4 2 6.9 years; education 15.0 2 2.1 years) were compared with 10 HIV-male gay or bisexual controls (ages 37.4 2 11.5 years; education 16.6 2 1.3 years). HIV seronegativity in the controls was documented by PCR testing. Proton magnetic resonance spectroscopy data has been presented for the majority of the samples presented here (Meyerhoff ~-et al., 1993 (Meyerhoff ~-et al., , 1994 (Meyerhoff ~-et al., , 1995 . Participants were recruited from advertisements in the San Francisco gay/bisexual newspapers, from flyers posted throughout the gay/bisexual neighborhoods in San Francisco, and from distribution of flyers describing the study to all HIV+ individuals enrolled in a local AIDS agency program that provides meals to HIV-infected individuals with mental or physical disabilities. Participants were excluded if they reported a history of drug or alcohol abuse, a major psychiatric disorder unrelated to or predating HIV infection, a head injury with loss of consciousness, brain disease other than HIV, or op- 
Neuropsychological Assessment
All participants underwent NP testing during which a wide range of cognitive skills (including attention, concentration, memory, verbal language, problem-solving, visuomotor and-visuospatial skills, and fine motor ability)
were assessed. The battery included (1) the WAIS-R Digit Symbol and Digit Span Subtests (Wechsler, 1981) ; (2) the Shipley Institute of Living Scale (Shipley, 1940) (Russell, 1975) ; (6) (Zachary norms, 1986) , the ReyOstemeth Complex Figure Test (Denman norms, 1984) , the Trail Making (Heaton et al. norms, 1991) , and the Finger Tapping and Grip Strength tests (raw scores). We then generated a global impairment score (GIS) by first scoring severity of clinical impairment for each test on a scale from 0 to 2. A participant received a score of 0 if he scored above the 15th percentile on the test, 1 if he scored in the 5th to 15th percentile, and 2 if he scored below the 5th percentile. Points earned on all tests were then summed. A participant was classified as not impaired if his GIs was 0 to 1, mildly to moderately impaired if his GIs was 2 to 5, and severely impaired if his GIS was 6 or more. All of the HIV-control subjects had a GIS of 0 to 1 (not impaired). 
MRI Acquisition
MRI studies were performed on a whole body Philips 2 Tesla MRIIMRS system. A sagittal T, weighted study (TRJTE = 450J30) was used for determination of the canthomeatal plane. This was followed by a spin-echo sequence (TRITE 3000/30/80 ms) performed parallel to the canthomeatid plane and covering the entire brain h m the cerebellum to the vertex. The spin-e@o sequence yielded a set of 19-to 24-proton density (the 30 ms echo) and T2 weighted (the 80 ms echo) 5.1 mm thick (with a 0.5 mm interslice gap) axial images.
MRI Analysis
Computer-assisted segmentation of the MRI into ventricular cerebrospinal fluid (CSF), sulcal CSF, gray matter, white matter, WMSHs, and caudate nuclei was performed for all subject by a single operator blind to participant identity. The undifferentiated-tissue-versus-CSF segmentation was performed on sequential slices beginning with the slice on which the red nucleus appeared and ending two slices above the last section on which the lateral ventricles were identified. The gray-versus-white-matter segmentation was performed on a subset of these slices, beginning with the fully volumed lateral ventricles and ending two slices above the last section on which the lateral ventricles were identified. Pixels that were classified by the discriminant analysis as gray matter but which must be white matter on the basis of anatomical location were manually changed to the WMSH classification. Qualitatively, most of the white matter displaying increased signal fell into a "diffuse," rather than "focal" classification; when focal areas of increased signal were present, these areas were subsumed in the WMSH category.
The head of the caudate was delineated on the addition image (i.e., the sum of the proton-density-weighted and T,-weighted images) on the slice on which the head of the caudate was most fully volumed. 
B.
developed by Lim et al. (1989) . The resulting image, which was subject to all remaining analyses, was limited to the boundaries of the intracranial vault. This was followed by estimation and removal of RF-field inhomogeneity by digital filtering. The inhomogeneity-corrected images were then processed by a trained operator blind to participant identity. On a slice-by-slice basis, the operator thresholded subtraction images (i.e., the difference image between the T,-and proton-density-weighted iniages) to specify conservative CSF and non-CSF samples. These samples were chosen to represent tissue that definitely belonged tothe correct (i.e., CSF or non-CSF) classification and left a sizable amount of tissue unclassified. For each slice, the conservative CSF and non-CSF samples were then used as training sets for a discriminant analysis that used both the protondensity-weighted and the T,-weighted pixel intensities to classify each pixel as either CSF or, non-CSF. Ventricular CSF was sepGated from sulcal CSF.by dividing the-area within the intracranial vault into two concentric subregions:
CSF within the inner 55% of the intracranial vault was designated as ventricular CSF and CSF in the outer 45% of the vault was designated as sulcal CSF. Ventricular and sulcal CSF volumes aggregated over the slices analyzed were then computed as a percent of the total intracranial vault volume to correct for variation in head size.
The gray-versus-white-matter discrimination was accomplished in a manner similar to the CSF versus non-CSF discrimination. On a slice-by-slice basis, the operator thresholded the addition image to specify conservative white matter and gray matter samples. These samples were chosen to represent tissue that definitely belonged to the correct (Le., white vs. gray) classification and left a sizable amount of tissue unclassified. For each slice, the conservative tissue samples were then used as training sets for a discriminant analysis which used both the proton-density-weighted and the T,-weighted pixel intensities to classii all non-CSF pixels as either gray or white matter. The white-matter and graymatter volumes aggregated over the slices analyzed were then computed as a percent of total intmmnial vault volume. The WMSH category was computed as a percent of total white matter-The volume of the head of the caudate was not correlated with total intraaaru 'al vault volume; therefore it was not corrected for the variation in head size. The interoperator correlations on a subset of 20 scans (both participants and controls) from this sample for percent CSF, percent white matter, percent WMSH, percent gray matter, and volume of the head of the caudate were -99, .82. -87, -66, and -83, respectively. In addition to the GIs, which was used to classify HIV+ subjects into impairment subgroups, a mean percentile score for all NP tests was calculated for each subject. The average NP percentile score for the control group was 65.1 5 4.64, the average NP percentile score for the nonimpaired HIV+ group was 60.6 2 1 1.6% [r(6) = 0.9 1, p = .398]. 
RESULTS
Neuropsychological Impairment versus Clinical Stage of HJY+ Participants
MRI Dierences &tween HIV-Controls and HIY+ Participants Classified by-Clinical
Stage of HIV Disease
The linear trend analysis presented in Table 4 and illustrated in Figure 2 demonstrates that percent ventricular and sulcal volume increased and gray matter percent and total caudate volume decreased with mom advanced clinical stage of HIV disease. For the purpose.,of this analysis, both controls and sage A were set to 1 (asymptomatic), stage B was set to 2, and stage C was set to 3. The linear trend analyses for gray-matter percent, ventricular and sulcal CSF percent, and caudate volume were all highly significant (all ps < .005). The effect of clinical stage membership accounted for 21.8 to 32.0% of the variance of the MRI variables that d esignificant atrophy. These effects are more than twice as large as those presented in Table 3 , where the HIV+ sample was not subdivided by clinical stage. Because clinical stage and 04% a n highly associated, an analysis of covariance was performed to determine if either variable In post hoc tests, there were no significant differences in any MRI measure between the controls and stage Aparticipants. The only significant difference between controls and stage B participants was an 8% decrease in caudate volume in Table 5 were much less dramatic than the linear trend analysis results for stage and MRI measures as shown in 
DISCUSSION
The major finding of this study is that MRI-detectable brain atrophy is strongly associated with CDC stage of systemic HIV disease and much more weakly associated with severity of NP impairment. When HIV+ subjects were sub-.- grouped by clinical stage, the MRI differences were directly and strongly associated with increasing seventy of systemic disease. When the same comparisons were made using level of NP impairment to create the subgroups, the MRI differences were only weakly associated with increasing severity of NP impairment. This conclusion is illustrated by the following results: (1) although half the patients in CDC stage A were severely I W impaired, the MRI measures of those subjects were not significantly different from those of controls, and (2) the mildly to moderately NP impaired group had the 1argesLapphic effects and the greatest number of individuals& CDC stage C. Everall et al.,: 1994) .
Neuronal damage by direct HIV infection of the CNS is likely to present a complicated picture, in that the neurotoxic pathways are linked and circular; H N stimulated cytokine production has been shown to lead to further expression of HIV (greater viral burden), so that further direct viral or cytokinemediated injury to the neuron may occur (Everall et al., 1994) . Furthermore, both anterograde cortical degeneration subsequent to subcortical lesions and retrograde degeneration of axons as the result of dendritic pathology may exacerbate the neuronal damage (Wiley et al., 1991) . Finally, even given this neuropathology, both Weis et al.
( 1 993) and Everall et al. (1994) failed to find any relationship between decreased neuronal density and NP impairment.
To our knowledge, there are no other studies in the neurological literature that compare the association of atrophic MRI changes with severity of systemic disease versus the association of atrophic MRI changes with severity of NP impairment. Because N p impairment and clinical stage of systemic dise'ase are confounded in most studies of HIVassociated brain atrophy, it has been very difficult to ascertain whether the relationship of morphological brain changes is to NP impairment, to stage of systemic disease, or to both.
For example, Hestad et ai. (1993) (Levin et al., 1990 , Moeller & Backmund, 1990 Post et al., 1991; Pan et al., 1992; Aylward et al., 1993; Hestad et al., 1993; Paley et al., 1994 In addition, the postmortem literature shows clear evidence of HIV associated damage to the white matter (Smith et al., 1990; Masliah et al., 1992a , Liuzzi et al., 1994 . We cannot account for the difference in our white matter findings. We do note that direct HIV invasion of the tissue and reactive gliosis are probable and opposing factors in atrophy. Masliah I et al. (199%) found that most white matter has minimal to moderate viral burden bu moderate to severe gliosis. Studdetecting group differences because of variation in both white matter loss and in degree of white matter gliosis. We also found no difference in percent WMSH between
HIv+ subjects and HN-controls, nor any association with the stage or N p subgroups. This finding has been replicated in the aforementioned study by Heaton et al. (1995) 
